¼¼°èÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå
Nucleotide
»óǰÄÚµå : 1791751
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 182 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀº 2030³â±îÁö 14¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 9¾ï 7,690¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ´ºÅ¬·¹¿ÀƼµå ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 14¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Deoxy Nucleotides´Â CAGR 7.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 8,110¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. RNA ÇÕ¼º¿ë ´ºÅ¬·¹¿ÀƼµå ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 5,680¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀº 2024³â¿¡ 2¾ï 5,680¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 6.1%·Î 2030³â±îÁö 2¾ï 2,640¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 6.1%¿Í 5.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.9%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´ºÅ¬·¹¿ÀŸÀ̵尡 ¿µ¾ç, Á¦¾à, »ý¸í°øÇп¡¼­ Àü·«Àû Á߿伺ÀÌ Ä¿Áö´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

DNA¿Í RNAÀÇ ±¸¼º¿ä¼ÒÀÎ À¯±âºÐÀÚÀÎ ´ºÅ¬·¹¿ÀƼµå´Â ´Ù¾çÇÑ »ê¾÷¿¡¼­ ºü¸£°Ô ¿ëµµ°¡ È®´ëµÇ°í ÀÖÀ¸¸ç, ±âº»ÀûÀÎ »ýÈ­ÇÐÀû ¼ººÐ¿¡¼­ °íºÎ°¡°¡Ä¡ ±â´É¼º ¼ººÐÀ¸·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î ´ºÅ¬·¹¿ÀƼµå´Â ¼¼Æ÷ ´ë»ç, À¯ÀüÁ¤º¸ ÀúÀå, ¿¡³ÊÁö Àü´Þ(ATP µî)¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ¿ÔÁö¸¸, ÇöÀç´Â À¯¾Æ ¿µ¾ç, µ¿¹°»ç·á¿¡¼­ ÀǾàǰ, »ý¸í°øÇп¡ À̸£±â±îÁö ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àΰ£ ¿µ¾ç ºÐ¾ß¿¡¼­´Â ¸é¿ª Áö¿ø, À§Àå ¹ß´Þ µî ¸ðÀ¯¿¡¼­ ¹ß°ßµÇ´Â ±â´ÉÀû ÀÌÁ¡À» ¸ð¹æÇϱâ À§ÇØ À¯¾Æ¿ë Á¶Á¦ ºÐÀ¯¿¡ ´ºÅ¬·¹¿ÀƼµå¸¦ ÷°¡ÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿¹° °Ç°­ ºÐ¾ß¿¡¼­´Â °¡Ãà »ç·á¿¡ ´ºÅ¬·¹¿ÀƼµå¸¦ ÷°¡ÇÏ¿© Àå °Ç°­, ¼ºÀå ¼º´É, Áúº´ ÀúÇ×¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÇÑÆí, Á¦¾à »ê¾÷¿¡¼­ ´ºÅ¬·¹¿ÀƼµå´Â Ç×¹ÙÀÌ·¯½ºÁ¦ ¹× Ç×¾ÏÁ¦ ÇÕ¼º¿¡¼­ Àü±¸Ã¼ ¹× Áß°£Ã¼·Î »ç¿ëµË´Ï´Ù. À¯ÀüÀÚ ¿¬±¸, Áø´Ü, Ä¡·á, ƯÈ÷ PCR ŰƮ, mRNA ÇÕ¼º, ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀÌµå ±â¹Ý Ä¡·á¿¡¼­ ´ºÅ¬·¹¿ÀŸÀ̵åÀÇ ¿ªÇÒÀº Äڷγª19 ÀÌÈÄ »õ·Î¿î ¸ð¸àÅÒÀ» ¾ò°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¹× »ý¸í°úÇÐ »ê¾÷ÀÌ ºü¸£°Ô ¼ºÀåÇÔ¿¡ µû¶ó ´ºÅ¬·¹¿ÀƼµå´Â À¯ÀüÀÚ Ä¡·á, ¹é½Å °³¹ß, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â(NGS) µî ÷´Ü ÀÀ¿ë ºÐ¾ßÀÇ ±âÃÊ ¿ø·á°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃÖÁ¾ ¿ëµµ ¿µ¿ªÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ´ºÅ¬·¹¿ÀƼµå´Â °Ç°­, °úÇÐ, Çõ½ÅÀÇ ±³Â÷Á¡¿¡ À§Ä¡Çϰí ÀÖÀ¸¸ç, ±× ½ÃÀå °¡Ä¡´Â ¹ü¿ë È­ÇÐÁ¦Ç°¿¡¼­ Àü·«Àû »ý¸í°úÇÐ ÅõÀÔ¹°·Î À̵¿Çϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀü°ú °øÁ¤ÀÇ ÃÖÀûÈ­´Â ¾î¶»°Ô Á¦Ç°ÀÇ ÁøÈ­¸¦ ÃËÁøÇϰí Àִ°¡?

¹ßÈ¿ ±â¼ú, È¿¼Ò ÇÕ¼º, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º °øÇÐÀÇ ¹ßÀüÀº ´ºÅ¬·¹¿ÀŸÀÌµå »ý»ê ¹æ¹ýÀ» ÀçÁ¤ÀÇÇÏ°í ¼öÀ², ¼øµµ, È®À强À» Çâ»ó½ÃÄÑ ±ÞÁõÇÏ´Â ½ÃÀå ¼ö¿ä¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. È¿¸ð ¹× ±âŸ õ¿¬ ÀÚ¿øÀ¸·ÎºÎÅÍÀÇ ÀüÅëÀûÀÎ ÃßÃâÀÌ ¿©ÀüÈ÷ ÀϹÝÀûÀÌÁö¸¸, Çö´ë »ê¾÷ °øÁ¤Àº ´õ ³ôÀº È¿À²¼º°ú Áö¼Ó°¡´É¼ºÀ» ´Þ¼ºÇϱâ À§ÇØ ¹Ì»ý¹° ¹ßÈ¿ ¹× È¿¼ÒÀû »ý¹° ÀüȯÀ» ¼±È£Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ¹ýÀº »ý»ê ºñ¿ëÀ» Àý°¨ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀǾàǰ ¹× ¿µ¾çÁ¦ ÀÀ¿ë ºÐ¾ß¿¡¼­ Áß¿äÇÑ ´ºÅ¬·¹¿ÀŸÀ̵åÀÇ ±¸¼º°ú ³óµµ¸¦ Á¤È®ÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦Á¶¾÷üµéÀº ÁÖ»çÁ¦ ¹× Ä¡·á¿ë Á¦Ç°ÀÇ Ãʼøµµ, GMP Áؼö ´ºÅ¬·¹¿ÀƼµå¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ´Ù¿î½ºÆ®¸² Á¤Á¦ ¹× °áÁ¤È­ ±â¼ú¿¡µµ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÈ­°¡ Áß¿äÇÑ Â÷º°È­ ¿ä¼Ò°¡ µÇ°í ÀÖÀ¸¸ç, À¯¾Æ¿ë ¿µ¾çÁ¦, ½ºÆ÷Ã÷ º¸ÃæÁ¦, ±â´É¼º ½Äǰ µî¿¡¼­´Â ƯÁ¤ °Ç°­ ±â´É¿¡ ¸Â°Ô ¸ÂÃãÇü ´ºÅ¬·¹¿ÀƼµå ºí·»µå¸¦ ó¹æÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¿Í ÇÕ¼º»ý¹°ÇÐÀÇ ºÎ»óÀº ´ºÅ¬·¹¿ÀƼµå ¾Æ³¯·Î±× ÇÕ¼ºÀ» À§ÇÑ »õ·Î¿î °æ·Î¸¦ ¿­¾î ÀǾàǰ °³¹ß ¹× À¯Àü°øÇп¡ Å« ÀáÀç·ÂÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­, ½Ç½Ã°£ °øÁ¤ ¸ð´ÏÅ͸µ, µ¥ÀÌÅÍ ±â¹Ý ÃÖÀûÈ­°¡ »ý»ê ¶óÀο¡ Á¡Á¡ ´õ ¸¹ÀÌ ÅëÇÕµÇ¾î ¹èÄ¡ Àϰü¼º, ±ÔÁ¤ Áؼö ¹× ȯ°æ Áö¼Ó°¡´É¼ºÀ» °­È­ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ °ø±Þ¾÷ü´Â ¹ë·ùüÀÎÀ» °³¼±Çϰí, ´ë·® ´ºÅ¬·¹¿ÀƼµå»Ó¸¸ ¾Æ´Ï¶ó Â÷¼¼´ë ÇコÄÉ¾î ¹× ¿µ¾ç Á¦Ç°¿¡ ½Å¼ÓÇÏ°Ô ÅëÇÕÇÒ ¼ö ÀÖ´Â ÀÀ¿ë °¡´ÉÇÏ°í ±â´ÉÀûÀ¸·Î °­È­µÈ º¯ÀÌü¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

°Ç°­ÀÌ ÃÖ¿ì¼±ÀÎ ¼¼°è °æÁ¦¿¡¼­ ´ºÅ¬·¹¿ÀŸÀ̵åÀÇ »ê¾÷À» ³Ñ¾î¼± ¼ö¿ä¸¦ ÃËÁøÇÏ´Â °ÍÀº ¹«¾ùÀΰ¡?

¸é¿ª °Ç°­, Áúº´ ¿¹¹æ, »ý¸í°øÇÐ Áß½ÉÀÇ ±â¼ú Çõ½Å¿¡ ´ëÇÑ Àü ¼¼°èÀÇ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ´ºÅ¬·¹¿ÀŸÀ̵åÀÇ ´ëÀÀ °¡´ÉÇÑ ½ÃÀåÀÌ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ ¿µ¾ç ºÐ¾ß¿¡¼­´Â ¿µÀ¯¾ÆÀÇ ¹ß´Þ°ú ¸é¿ª¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ´ºÅ¬·¹¿ÀƼµå ºí·»µå¸¦ Æ÷ÇÔÇÑ °­È­ À¯¾Æ¿ë Á¶Á¦ºÐÀ¯¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ¸é¿ª·Â °­È­¿Í ÇǷΠȸº¹À» ÃËÁøÇÏ´Â º¸ÃæÁ¦¸¦ ã´Â ¼ºÀεéÀÌ ½Äǰ ¹× °Ç°­±â´É½Äǰ ºê·£µå¿¡ ´ºÅ¬·¹¿ÀƼµå¸¦ ±â´É¼º Á¦Ç° Æ÷Æ®Æú¸®¿À¿¡ Æ÷ÇÔ½Ã۵µ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù. Ãà»ê¾÷¿¡¼­ Ç×»ýÁ¦ »ç¿ëÀÌ ÁÙ¾îµé¸é¼­ ´ºÅ¬·¹¿ÀƼµå´Â °¡ÃàÀÇ ¼º´É ¹× Áúº´ ÀúÇ×¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ ±ÍÁßÇÑ ´ëüÀç, ƯÈ÷ °¡±Ý·ù, ¾çµ·, ¾ç½Ä¾÷ ºÐ¾ß¿¡¼­ ´ëüÀç·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ºÐ¾ß¿¡¼­ PCR ½Ã¾à, RNA ±â¹Ý ÀǾàǰ, Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Æø¹ßÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ´ºÅ¬·¹¿ÀƼµå´Â ¿¬±¸¼Ò¿Í Á¦¾àȸ»ç¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. Äڷγª19 ÆÒµ¥¹ÍÀº ÀÌ·¯ÇÑ Ãß¼¼ÀÇ ±âÆøÁ¦°¡ µÇ¾î ½Å¼Ó ¹ÝÀÀ ¹é½Å °³¹ß ¹× Áø´Ü Å×½ºÆ® »ý»ê¿¡¼­ ´ºÅ¬·¹¿ÀƼµå ºôµù ºí·ÏÀÇ Àü·«Àû ¿ªÇÒÀ» °­È­Çß½À´Ï´Ù. ÀǾàǰ Á¦Á¶¿¡¼­´Â ´ºÅ¬·¹¿ÀƼµå°¡ ÇÕ¼º ÀǾàǰ ¿ø·á, ƯÈ÷ Ç×¹ÙÀÌ·¯½ºÁ¦³ª ¾Ï Ä¡·áÁ¦ÀÇ Ãâ¹ß ¿ø·á·Î »ç¿ëµÇ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CRISPR ±â¼ú, À¯ÀüÀÚ ÆíÁý, ÇÕ¼º ¹é½ÅÀÇ »õ·Î¿î ÀÌ¿ë »ç·Ê´Â »õ·Î¿î »ó¾÷Àû ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Á¤¹ÐÀÇ·á, ¸é¿ª ȸº¹·Â, Á¶±â °³ÀÔ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ´Â °¡¿îµ¥, ´ºÅ¬·¹¿ÀƼµå´Â Ä¡·á Àü·«°ú ¿¹¹æ ÀÇ·á Á¦Ç°¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »ê¾÷ Àü¹Ý ¼ö¿ä´Â ¼ÒºñÀÚÀÇ °Ç°­ ÀǽÄ, ³ó¾÷ÀÇ º¯È­, »ý¹°ÀÇÇÐ Çõ½ÅÀÇ ¼ö·ÅÀ» ¹Ý¿µÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¸ðµÎ ¼¼°è ¹ÙÀÌ¿À °æÁ¦¿¡¼­ ´ºÅ¬·¹¿ÀƼµåÀÇ ¿ªÇÒÀÌ °ß°íÇϰí È®´ëµÇ°í ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

´ºÅ¬·¹¿ÀƼµå ¼¼°è ½ÃÀå ¼ºÀå ¿øµ¿·ÂÀº?

´ºÅ¬·¹¿ÀŸÀÌµå ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Çõ½Å, ÃÖÁ¾ ¿ëµµ ÁøÈ­, ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø, ¼ÒºñÀÚ ¹× »ê¾÷°èÀÇ ¿ì¼±¼øÀ§ º¯È­¿Í °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, ¿µÀ¯¾Æ ¿µ¾ç, ±â´É¼º ½Äǰ, µ¿¹°»ç·á¿¡ ´ëÇÑ Àû¿ë È®´ë·Î ¸é¿ª, ¼ÒÈ­, °Ç°­ Àü¹ÝÀ» Áö¿øÇÏ´Â ´ºÅ¬·¹¿ÀƼµå °­È­ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µÑ°, ÀǾàǰ ÇÕ¼º, ¹é½Å °³¹ß, À¯ÀüÀÚ Ä¡·á¿¡¼­ ¹ÙÀÌ¿À Á¦¾à »ê¾÷ÀÇ ´ºÅ¬·¹¿ÀƼµå ÀÇÁ¸µµ°¡ ³ô¾ÆÁö¸é¼­, ƯÈ÷ Àü ¼¼°è °¨¿°º´ ´ëÃ¥¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼Â°, »ý¸í°øÇаú À¯Àü°øÇÐÀÇ ¹ßÀüÀ¸·Î ´ºÅ¬·¹¿ÀƼµå´Â ¿ø·á¿¡¼­ Áø´Ü¾à, mRNA Ä¡·áÁ¦, ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÀǾàǰ, DNA ½ÃÄö½Ì ±â¼ú¿¡ ÇʼöÀûÀÎ ±¸¼º ¿ä¼Ò·Î ½ÂÈ­µÇ¾ú½À´Ï´Ù. ³Ý°, Àü ¼¼°è ±ÔÁ¦ ´ç±¹ÀÌ ½Äǰ, »ç·á, ÀǾàǰ¿¡ ´ºÅ¬·¹¿ÀƼµå¸¦ Æ÷ÇÔÇÏ´Â °ÍÀ» ½ÂÀÎÇϰí ÀÖ¾î Á¦Ç°ÀÇ Á¤´ç¼ºÀ» ³ôÀÌ°í »ó¾÷Àû äÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ´Ù¼¸Â°, Á¦Á¶¾÷ü´Â ȯ°æ°ú ºñ¿ë È¿À²¼ºÀÇ ¸ñÇ¥¿¡ µû¶ó »ý»ê¹°ÀÇ Ç°ÁúÀ» Çâ»ó½ÃŰ¸é¼­ ȯ°æ ģȭÀûÀ̰í È®Àå °¡´ÉÇÑ »ý»ê ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿©¼¸Â°, Ç×»ýÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê´Â °¡Ãà »ý»ê¿¡ ´ëÇÑ ¿òÁ÷ÀÓÀÌ Ãµ¿¬ ¼ºÀå ÃËÁøÁ¦ ¹× ¸é¿ª Á¶ÀýÁ¦·Î¼­ ´ºÅ¬·¹¿ÀƼµå¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °Ç°­±â´É½ÄǰÀÇ ÀüÀÚ»ó°Å·¡ ¼ºÀå°ú D2C À¯ÅëÀº Áö¿ª°ú ¼ÒºñÀÚ ºÎ¹®À» ³Ñ¾î Á¦Ç° µµ´Þ ¹üÀ§¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ´ºÅ¬·¹¿ÀŸÀÌµå ½ÃÀåÀº ´ÙºÐ¾ß¿¡ °ÉÃÄ Áö¼Ó °¡´ÉÇÑ ¼ºÀåÀ» °¡¼ÓÇÏ°í »ý¸í°úÇÐ, ¿µ¾ç ¹× ¹ÙÀÌ¿À °¡°ø »ê¾÷¿¡¼­ °íºÎ°¡°¡Ä¡ ºÎ¹®À¸·Î È®°íÇÑ ÀÔÁö¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(µ¥¿Á½Ã´ºÅ¬·¹¿ÀŸÀ̵å, RNA ÇÕ¼º¿ë ´ºÅ¬·¹¿ÀŸÀ̵å, µðµ¥¿Á½Ã´ºÅ¬·¹¿ÀŸÀ̵å, Ç¥Áö ´ºÅ¬·¹¿ÀŸÀ̵å); ±â¼ú(TaqMan ´ë¸³À¯ÀüÀÚ ÆÇº° ±â¼ú, ÆÄÀ̷νÃÄö½Ì ±â¼ú¿¡ ÀÇÇÑ SNP, À¯ÀüÀÚ Ä¨ ¹× ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼ú, ±âŸ ±â¼ú); ÀÀ¿ë(Áø´Ü ¿¬±¸ ÀÀ¿ë, Á¦¾à ÀÀ¿ë, ½ÄÀ½·á ÷°¡Á¦ ÀÀ¿ë, µ¿¹° »ç·á ÷°¡¹° ÀÀ¿ë, ±âŸ ÀÀ¿ë).

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Nucleotide Market to Reach US$1.4 Billion by 2030

The global market for Nucleotide estimated at US$976.9 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Deoxy Nucleotides, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$681.1 Million by the end of the analysis period. Growth in the Nucleotides for RNA Synthesis segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$256.8 Million While China is Forecast to Grow at 6.1% CAGR

The Nucleotide market in the U.S. is estimated at US$256.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$226.4 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Nucleotide Market - Key Trends & Drivers Summarized

Why Are Nucleotides Gaining Strategic Importance Across Nutrition, Pharmaceuticals, and Biotech?

Nucleotides-organic molecules that serve as the building blocks of DNA and RNA-are finding rapidly expanding applications across a variety of industries, transforming them from basic biochemical components into high-value functional ingredients. Traditionally known for their essential role in cellular metabolism, genetic information storage, and energy transfer (e.g., ATP), nucleotides are now in high demand in sectors ranging from infant nutrition and animal feed to pharmaceuticals and biotechnology. In human nutrition, nucleotides are increasingly added to infant formula to mimic the functional benefits found in breast milk, such as enhanced immune support and gastrointestinal development. In animal health, nucleotide supplementation in livestock feed improves gut health, growth performance, and disease resistance-especially in antibiotic-free production systems. Meanwhile, in the pharmaceutical industry, nucleotides are used as precursors or intermediates in the synthesis of antiviral and anticancer drugs. Their role in genetic research, diagnostics, and therapeutics, particularly in PCR kits, mRNA synthesis, and oligonucleotide-based treatments, has gained new momentum post-COVID-19. With biotech and life sciences industries expanding rapidly, nucleotides are becoming a foundational raw material in advanced applications such as gene therapy, vaccine development, and next-generation sequencing (NGS). As these end-use domains continue to evolve, nucleotides are positioned at the intersection of health, science, and innovation-shifting their market value from commodity chemicals to strategic bioscience inputs.

How Are Technological Advancements and Process Optimization Driving Product Evolution?

Advancements in fermentation technology, enzymatic synthesis, and bioprocess engineering are redefining how nucleotides are produced, improving yield, purity, and scalability to meet surging market demand. While traditional extraction from yeast or other natural sources remains common, modern industrial processes now favor microbial fermentation and enzymatic bioconversion for higher efficiency and sustainability. These methods not only reduce production costs but also allow for precise control over nucleotide composition and concentration-critical in pharmaceutical and nutritional applications. Manufacturers are also investing in downstream purification and crystallization technologies to meet the growing need for ultra-pure, GMP-compliant nucleotides in injectable and therapeutic products. Further, customization is becoming a key differentiator, with tailored nucleotide blends being formulated for specific health functions in infant nutrition, sports supplements, and functional foods. The rise of bioinformatics and synthetic biology is also unlocking novel pathways for nucleotide analog synthesis, which holds significant promise in drug development and genetic engineering. Automation, real-time process monitoring, and data-driven optimization are increasingly being integrated into production lines, enhancing batch consistency, regulatory compliance, and environmental sustainability. These innovations are enabling suppliers to move up the value chain-offering not just bulk nucleotides, but application-ready, functionally enhanced variants that can be quickly integrated into next-gen healthcare and nutrition products.

What’s Fueling Cross-Industry Demand for Nucleotides in a Health-First Global Economy?

The growing global emphasis on immune health, disease prevention, and biotechnology-driven innovation is significantly expanding the addressable market for nucleotides. In the consumer nutrition sector, increased awareness of early-life development and immunity is driving demand for fortified infant formulas containing nucleotide blends. Similarly, adults seeking immune-supporting or recovery-enhancing supplements are pushing food and nutraceutical brands to include nucleotides in functional product portfolios. The shift away from antibiotics in animal agriculture has made nucleotides a valuable alternative for improving livestock performance and disease resistance-especially in poultry, swine, and aquaculture sectors. In biotechnology, the explosion in demand for PCR reagents, RNA-based drugs, and diagnostic tools has made nucleotides indispensable to research labs and pharmaceutical manufacturers alike. The COVID-19 pandemic acted as a catalyst for this trend, reinforcing the strategic role of nucleotide building blocks in rapid-response vaccine development and diagnostic test production. In pharmaceutical manufacturing, nucleotides are increasingly used as starting materials for synthetic drug APIs, especially antivirals and oncology drugs. Additionally, emerging use cases in CRISPR technologies, genetic editing, and synthetic vaccines are opening new commercial pathways. As healthcare systems worldwide focus on precision medicine, immune resilience, and early intervention, nucleotides are becoming integral to therapeutic strategies and preventive health products. This cross-industry demand reflects a convergence of consumer health consciousness, agricultural transformation, and biomedical innovation-all pointing toward a robust and expanding role for nucleotides in the global bioeconomy.

What’s Driving the Growth of the Global Nucleotide Market?

The growth in the nucleotide market is driven by several factors tied to technological innovation, evolving end-use applications, regulatory support, and shifts in consumer and industrial priorities. First, expanding applications in infant nutrition, functional foods, and animal feed are creating consistent demand for nucleotide-fortified products that support immunity, digestion, and overall wellness. Second, the biopharmaceutical industry's rising reliance on nucleotides for drug synthesis, vaccine development, and gene therapy is significantly boosting market demand-particularly in the wake of global infectious disease preparedness initiatives. Third, advancements in biotechnology and genetic engineering have elevated nucleotides from raw materials to essential building blocks in diagnostics, mRNA therapeutics, oligonucleotide drugs, and DNA sequencing technologies. Fourth, regulatory authorities across the globe are increasingly approving nucleotide inclusion in food, feed, and pharma formulations, enhancing the product's legitimacy and accelerating commercial adoption. Fifth, manufacturers are investing in green, scalable production technologies that improve output quality while aligning with environmental and cost-efficiency goals. Sixth, the move toward antibiotic-free livestock production is stimulating demand for nucleotides as a natural growth enhancer and immune modulator. Furthermore, e-commerce growth and D2C distribution in nutraceuticals are expanding product reach across geographies and consumer segments. Together, these factors are driving sustained, multi-sectoral growth in the nucleotide market, firmly positioning it as a high-value segment within the life sciences, nutrition, and bioprocessing industries.

SCOPE OF STUDY:

The report analyzes the Nucleotide market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides, Labelled Nucleotides); Technology (TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology, Other Technologies); Application (Diagnostics Research Application, Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â